Shares of XOMA Co. (NASDAQ:XOMA – Get Rating) have been assigned a consensus rating of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $49.00.
XOMA has been the subject of a number of recent research reports. Zacks Investment Research downgraded XOMA from a “hold” rating to a “strong sell” rating in a research report on Saturday, January 8th. StockNews.com downgraded XOMA from a “buy” rating to a “hold” rating in a research report on Friday, April 22nd. Finally, TheStreet upgraded XOMA from a “c-” rating to a “b-” rating in a research report on Friday, April 1st.
In other XOMA news, CFO Thomas M. Burns sold 2,339 shares of the stock in a transaction on Tuesday, March 22nd. The shares were sold at an average price of $30.02, for a total transaction of $70,216.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO James R. Neal sold 1,111 shares of the firm’s stock in a transaction on Wednesday, March 23rd. The stock was sold at an average price of $30.02, for a total transaction of $33,352.22. The disclosure for this sale can be found here. Insiders sold a total of 53,450 shares of company stock valued at $1,553,569 in the last 90 days. 9.89% of the stock is currently owned by corporate insiders.
Shares of NASDAQ XOMA opened at $19.23 on Friday. XOMA has a 12 month low of $18.82 and a 12 month high of $39.49. The firm has a market capitalization of $219.15 million, a price-to-earnings ratio of 128.21 and a beta of 0.89. The business has a 50-day moving average of $24.92 and a 200-day moving average of $23.28.
XOMA (NASDAQ:XOMA – Get Rating) last issued its quarterly earnings data on Tuesday, March 8th. The biotechnology company reported $1.67 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.27 by ($0.60). XOMA had a return on equity of 4.93% and a net margin of 14.57%. The business had revenue of $35.94 million for the quarter, compared to analysts’ expectations of $34.84 million.
About XOMA (Get Rating)
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.
- Get a free copy of the StockNews.com research report on XOMA (XOMA)
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- O’Reilly Automotive Hits A Pothole
Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.